FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:352-357 February 9, 1989 Number 6 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We performed a double-blind randomized trial comparing high doses of subcutaneous heparin (12,500 units every 12 hours) with low doses (5000 units every 12 hours) for 10 days in the prevention of left ventricular mural thrombosis in 221 patients with acute anterior myocardial infarction. Left ventricular mural thrombosis was observed by two-dimensional echocardiography on the 10th day after infarction in 10 of 95 patients (11 percent) in the high-dose group and in 28 of 88 patients (32 percent) in the low-dose group (P = 0.0004). One patient in the high-dose group and four in the low-dose group had nonhemorrhagic strokes (P = 0.17). One patient in the low-dose group had a fatal pulmonary embolism. There was no difference in the frequency of hemorrhagic complications, which occurred in six patients in the high-dose group and four in the low-dose group. The mean (+/- SEM) plasma heparin concentration was 0.18 +/- 0.017 U per milliliter in the high-dose group and 0.01 +/- 0.005 U per milliliter in the low-dose group (P less than 0.0001). In the high-dose group, the mean plasma heparin concentration was 0.10 +/- 0.029 U per milliliter among patients with abnormal two-dimensional echocardiograms, as compared with 0.19 +/- 0.019 U per milliliter among patients with normal echocardiograms (P = 0.01). We conclude that heparin administered subcutaneously in a dosage of 12,500 units every 12 hours to patients with acute anterior transmural myocardial infarction is more effective than a lower dosage (5000 units every 12 hours) in preventing left ventricular mural thrombosis.

Source Information

Department of Medicine, McMaster University, Hamilton, Ont., Canada.

This article has been cited by other articles:

• Newall, F., Johnston, L., Ignjatovic, V., Monagle, P. (2009). Unfractionated Heparin Therapy in Infants and Children. Pediatrics 123: e510-e518 [Abstract] [Full Text]  
• Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., Weitz, J. I. (2008). Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 141S-159S [Abstract] [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]  
• Spinler, S. A, Wittkowsky, A. K, Nutescu, E. A, Smythe, M. A (2005). Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin. The Annals of Pharmacotherapy 39: 1275-1285 [Abstract] [Full Text]  
• Smythe, M. A., Caffee, A. (2004). Anticoagulation Monitoring. Journal of Pharmacy Practice 17: 317-326 [Abstract]  
• Hirsh, J., Raschke, R. (2004). Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S [Abstract] [Full Text]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• Montalescot, G., Collet, J.P., Tanguy, M.L., Ankri, A., Payot, L., Dumaine, R., Choussat, R., Beygui, F., Gallois, V., Thomas, D. (2004). Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin. Circulation 110: 392-398 [Abstract] [Full Text]  
• Hylek, E. M., Regan, S., Henault, L. E., Gardner, M., Chan, A. T., Singer, D. E., Barry, M. J. (2003). Challenges to the Effective Use of Unfractionated Heparin in the Hospitalized Management of Acute Thrombosis. Arch Intern Med 163: 621-627 [Abstract] [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio. 21 : e9-e9 [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation 103: 2994-3018 [Full Text]  
• Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., Dalen, J. E. (2001). Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest 119 : 64S-94S [Full Text]  
• Levine, M. N., Raskob, G., Landefeld, S., Kearon, C. (2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest 119 : 108S-121S [Full Text]  
• Cairns, J. A., Theroux, P., Lewis, H. D. Jr., Ezekowitz, M., Meade, T. W. (2001). Antithrombotic Agents in Coronary Artery Disease. Chest 119 : 228S-252S [Full Text]  
• Kapral, M. K., Silver, F. L. (1999). Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. CMAJ 161: 989-996 [Abstract] [Full Text]  
• Swanson, R. A. (1999). Intravenous heparin for acute stroke: What can we learn from the megatrials?. Neurology 52: 1746-1746 [Abstract] [Full Text]  
• Zhao, M., Abdel-Razek, T., Sun, M.-F., Gailani, D. (1998). Characterization of a Heparin Binding Site on the Heavy Chain of Factor XI. J. Biol. Chem. 273: 31153-31159 [Abstract] [Full Text]  
• Baker, W. F. JR (1998). Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I). CLIN APPL THROMB HEMOST 4: 51-75 [Abstract]  
• Baker, B. A., Adelman, M. D., Smith, P. A., Osborn, J. C. (1997). Inability of the Activated Partial Thromboplastin Time to Predict Heparin Levels: Time to Reassess Guidelines for Heparin Assays. Arch Intern Med 157: 2475-2479 [Abstract]  
• Anand, S., Ginsberg, J. S., Hirsh, J. (1997). Is There a Relationship Between the Intensity of Heparin Treatment and Recurrent Thomboembolism?. CLIN APPL THROMB HEMOST 3: S64-S67 [Abstract]  
• Mooe, T., Eriksson, P., Stegmayr, B. (1997). Ischemic Stroke After Acute Myocardial Infarction : A Population-Based Study. Stroke 28: 762-767 [Abstract] [Full Text]  
• Deedwania, P. C., Amsterdam, E. A., Vagelos, R. H. (1997). Evidence-Based, Cost-effective Risk Stratification and Management After Myocardial Infarction. Arch Intern Med 157: 273-280 [Abstract]  
• Loh, E., Sutton, M. St. J., Wun, C.-C. C., Rouleau, J. L., Flaker, G. C., Gottlieb, S. S., Lamas, G. A., Moye, L. A., Goldhaber, S. Z., Pfeffer, M. A. (1997). Ventricular Dysfunction and the Risk of Stroke after Myocardial Infarction. NEJM 336: 251-257 [Abstract] [Full Text]  
• Collins, R., MacMahon, S., Flather, M., Baigent, C., Remvig, L., Mortensen, S., Appleby, P., Godwin, J., Yusuf, S., Peto, R. (1996). Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 313: 652-659 [Abstract] [Full Text]  
• Raschke, R. A., Gollihare, B., Peirce, J. C. (1996). The Effectiveness of Implementing the Weight-Based Heparin Nomogram as a Practice Guideline. Arch Intern Med 156: 1645-1649 [Abstract]  
• Pearson, S. D., Polak, J. L., Cartwright, S., McCabe-Hassan, S., Lee, T. H., Goldhaber, S. Z. (1995). A Critical Pathway to Evaluate Suspected Deep Vein Thrombosis. Arch Intern Med 155: 1773-1778 [Abstract]  
• Granger, C. B., Miller, J. M., Bovill, E. G., Gruber, A., Tracy, R. P., Krucoff, M. W., Green, C., Berrios, E., Harrington, R. A., Ohman, E. M., Califf, R. M. (1995). Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin in Patients With Acute Coronary Syndromes. Circulation 91: 1929-1935 [Abstract] [Full Text]  
• Gunnarsson, P. S., Sawyer, W. T., Montague, D., Williams, M. L., Dupuis, R. E., Caiola, S. M. (1995). Appropriate Use of Heparin: Empiric vs Nomogram-Based Dosing. Arch Intern Med 155: 526-532 [Abstract]  
• Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Leclerc, J., Powers, P. J., Jay, R. M., Neemeh, J. (1991). Prevention of Deep Vein Thrombosis after Elective Hip Surgery: A Randomized Trial Comparing Low Molecular Weight Heparin with Standard Unfractionated Heparin. ANN INTERN MED 114: 545-551 [Abstract]  
• Becker, R. C., Alpert, J. S. (1990). The Impact of Medical Therapy on Hemorrhagic Complications Following Coronary Artery Bypass Grafting. Arch Intern Med 150: 2016-2021 [Abstract]  
• Gore, J. M., Dalen, J. E. (1990). Cardiovascular Disease. JAMA 263: 2629-2631 [Abstract]  
• (1989). Cardiogenic Brain Embolism: The Second Report of the Cerebral Embolism Task Force. Arch Neurol 46: 727-743 [Abstract]